Rimonabant for the treatment of obesity

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 3, 2008, Pages 187-193

  Samat, Ashish ^a   Tomlinson, Brian ^b   Taheri, Shahrad ^c   Thomas, G Neil ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

ARPEGGIO; AUDITOR; CRESCENDO; Endocannabinoid system; Obesity; RAPSODI; Rimonabant; RIO ADAGIO Lipids; SERENADE; STRADIVARIUS; Vascular disease risk factors; VICTORIA; Visceral fat

Indexed keywords

2 (2 HYDROXYPHENYL)BENZIMIDAZOLE DERIVATIVE; ANTIDEPRESSANT AGENT; CANNABINOID RECEPTOR ANTAGONIST; DIGOXIN; ENDOCANNABINOID; GLITAZONE DERIVATIVE; HALOALKYLSULFONE DERIVATIVE; INSULIN; METFORMIN; MIDAZOLAM; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL OBESITY; ANXIETY; CLINICAL TRIAL; DEPRESSION; DIET THERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MAJOR DEPRESSION; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATENT; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION;

CLINICAL TRIALS AS TOPIC; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID;

EID: 58149190820     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008786264014     Document Type: Review

References (52)

1. U.S. Department of Health & Human Services. Washington, DC, 2008. http://wwwsurgeongeneralgov/topics/obesity/calltoaction/ fact_whatcanyoudohtm. Overweight and Obesity: What You Can Do?
2. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
3. Adams K, Schatzkin A, Harris T, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763-778.
4. Hu G, Tuomilehto J, Silventoinen K, Barengo NC, Peltonen M, Jousilahti P. The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47 212 middle-aged Finnish men and women. Int J Obes Relat Metab Disord 2005; 29: 894-902.
5. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995; 273: 461-465.
6. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685.
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638.
8. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ 2007; 335: 1134.
9. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000; 160: 898-904.
10. Thomas GN, Ho S-Y, Lam KSL, et al. For the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. Impact of obesity and body fat distribution on cardiovascular risk factors in Hong Kong Chinese. Obes Res 2004; 12: 1805-1813.
11. Thomas GN, Schooling M, McGhee SM, et al. For the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. Metabolic syndrome increases all-cause and vascular mortality: The Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol 2007; 66: 666-671.
12. Mann DM, Lee J, Liao Y, Natarajan S. Independent effect and population impact of obesity on fatal coronary heart disease in adults. Prev Med 2006; 42: 66-72.
13. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843-1848.
14. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-952.
15. Leung WYS, Thomas GN, Chan JCN, Tomlinson B. Weight management and current options in pharmacotherapy: Orlistat and Sibutramine. Clin Therapeut 2003; 25: 58-80.
16. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes 2007; 31: 1567-1570.
17. Abel EL. Cannabis: Effects on hunger and thirst. Behav Biol 1975; 15: 255-281.
18. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
19. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
20. Di Marzo V, Goparju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
21. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557.
22. Jamshidi N, Taylor DA. Anandamide administration into ventromedial hypothamalmus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151-1154.
23. Gómez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617.
24. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
25. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB, receptor antagonist SR141716 increases Acrp 30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
26. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes Care 2005; 54: 2838-2843.
27. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 2005; 29: 755-759.
28. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: A systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007; 107: 1755-1767.
29. Aucott L, Poobalan A, Smith WC, et al. Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes-a systematic review. Diabetes Obes Metab 2004; 6: 85-94.
30. McTigue KM, Hess R, Ziouras J. Obesity in older adults: A systematic review of the evidence for diagnosis and treatment. Obesity 2006; 14: 1485-1497.
31. World Health Organization. Obesity: Preventing and managing the global epidemic. Geneva: World Health Organization, 1998.
32. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type-2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
33. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: Clinical significance and applicability to clinical practice. Int J Obes 2005; 29: 1153-1167.
34. Pi-Sunyer FX. The effects of pharmacologic agents for type-2 diabetes mellitus on body weight. Postgrad Med J 2008; 120: 5-17.
35. Turpault S, Kanamaluru V, Lockwood GF, Bonnet D, Newton J. Rimonabant pharmacokinetics in healthy and obese subjects. Clin Pharmacol Therapeut 2005; 79 (2): P50.
36. Dholakia, P.N., Dave, M.G., Pandey, B., Patel, P.R.: WO08056377 (2008).
37. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circ Res 2006; 114: 974-984.
38. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006: CD006162. DOI:006110.001002/ 14651858.CD14006162.pub14651852.
39. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight loss drug rimonabant: A meta-analysis of randomised trials. Lancet Neurol 2007; 370: 1706-1713.
40. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006; 295: 761-775.
41. Simons-Morton DG, Obarzanek E, Cutler JA. Obesity research-limitations of methods, measurements, and medications. JAMA 2006; 295: 826-828.
42. Després J-P, Golay A, Sjöström L. For the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
43. Nissen SE, Nicholls SJ, Wolski K, et al. STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial. JAMA 2008; 299(13): 1547-1560.
44. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type-2 diabetes: A randomised controlled study. Lancet 2006; 368: 1660-1672.
45. Iranmanesh A, Rosenstock J, Hollander P. On behalf of the SERENADE study group. SERENADE: Rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naive patients with type 2 diabetes. Diabetic Med 2006; 23(4): 230.
46. Briefing Information, NDA 21-888 ZIMULTI (rimonabant)-Sanofi-Aventis. Food and Drug Adminstration Endocrinologic and Metabolic Advisiory 2007; June13, 2007.
47. http://en.wikipedia.org/wiki/Rimonabant. Rimonabant, 2008.
48. Gibson HE, Edwards JG, Page RS, Van Hook MJ, Kauer JA. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 2008; 57: 746-759.
49. Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome. Physiol Behav 2008; 93: 671-686.
50. Olesen, P.H., Petersen, A.K., Nielsen, F.E., Christiansen, L.B., Hansen, H.C.: WO08059026 (2008).
51. Olesen, P.H., Petersen, A.K., Nielsen, F.E., Christiansen, L.B.: WO08059023 (2008).
52. European Medicines Agency. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ acomplia/53777708en.pdf. Accessed on 4 Nov. 2008.